Logo image of FDMT

4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:FDMT - US35104E1001 - Common Stock

11.23 USD
+0.53 (+4.95%)
Last: 12/4/2025, 2:57:01 PM
Fundamental Rating

3

FDMT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. FDMT has a great financial health rating, but its profitability evaluates not so good. FDMT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FDMT had negative earnings in the past year.
In the past year FDMT has reported a negative cash flow from operations.
FDMT had negative earnings in each of the past 5 years.
In the past 5 years FDMT always reported negative operating cash flow.
FDMT Yearly Net Income VS EBIT VS OCF VS FCFFDMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -41.41%, FDMT perfoms like the industry average, outperforming 59.18% of the companies in the same industry.
FDMT has a better Return On Equity (-46.60%) than 67.98% of its industry peers.
Industry RankSector Rank
ROA -41.41%
ROE -46.6%
ROIC N/A
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
FDMT Yearly ROA, ROE, ROICFDMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

FDMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FDMT Yearly Profit, Operating, Gross MarginsFDMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K -500K

More info and screens

8

2. Health

2.1 Basic Checks

FDMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FDMT has more shares outstanding
Compared to 5 years ago, FDMT has more shares outstanding
FDMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FDMT Yearly Shares OutstandingFDMT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
FDMT Yearly Total Debt VS Total AssetsFDMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

FDMT has an Altman-Z score of 4.09. This indicates that FDMT is financially healthy and has little risk of bankruptcy at the moment.
FDMT has a Altman-Z score of 4.09. This is in the better half of the industry: FDMT outperforms 71.54% of its industry peers.
There is no outstanding debt for FDMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.09
ROIC/WACCN/A
WACC8.73%
FDMT Yearly LT Debt VS Equity VS FCFFDMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 8.75 indicates that FDMT has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.75, FDMT is doing good in the industry, outperforming 77.90% of the companies in the same industry.
A Quick Ratio of 8.75 indicates that FDMT has no problem at all paying its short term obligations.
FDMT's Quick ratio of 8.75 is fine compared to the rest of the industry. FDMT outperforms 77.90% of its industry peers.
Industry RankSector Rank
Current Ratio 8.75
Quick Ratio 8.75
FDMT Yearly Current Assets VS Current LiabilitesFDMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

FDMT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.51%.
FDMT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.82%.
The Revenue for FDMT have been decreasing by -64.95% on average. This is quite bad
EPS 1Y (TTM)-32.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.85%
Revenue 1Y (TTM)-99.82%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%2900%

3.2 Future

FDMT is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -6.84% yearly.
The Revenue is expected to grow by 132.60% on average over the next years. This is a very strong growth
EPS Next Y-26.44%
EPS Next 2Y-12.42%
EPS Next 3Y-10.64%
EPS Next 5Y-6.84%
Revenue Next Year105.44%
Revenue Next 2Y47.6%
Revenue Next 3Y40.14%
Revenue Next 5Y132.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FDMT Yearly Revenue VS EstimatesFDMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
FDMT Yearly EPS VS EstimatesFDMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FDMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FDMT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FDMT Price Earnings VS Forward Price EarningsFDMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FDMT Per share dataFDMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as FDMT's earnings are expected to decrease with -10.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.42%
EPS Next 3Y-10.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FDMT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

4D MOLECULAR THERAPEUTICS IN

NASDAQ:FDMT (12/4/2025, 2:57:01 PM)

11.23

+0.53 (+4.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners86.98%
Inst Owner Change-6.13%
Ins Owners3.85%
Ins Owner Change-0.3%
Market Cap641.68M
Revenue(TTM)37.00K
Net Income(TTM)-196.14M
Analysts81.25
Price Target33.77 (200.71%)
Short Float %9.38%
Short Ratio5.89
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.75%
Min EPS beat(2)-9.71%
Max EPS beat(2)2.21%
EPS beat(4)1
Avg EPS beat(4)-6.46%
Min EPS beat(4)-10.47%
Max EPS beat(4)2.21%
EPS beat(8)5
Avg EPS beat(8)7.58%
EPS beat(12)8
Avg EPS beat(12)6.75%
EPS beat(16)11
Avg EPS beat(16)5.29%
Revenue beat(2)0
Avg Revenue beat(2)-96.24%
Min Revenue beat(2)-96.41%
Max Revenue beat(2)-96.07%
Revenue beat(4)0
Avg Revenue beat(4)-97.97%
Min Revenue beat(4)-99.94%
Max Revenue beat(4)-96.07%
Revenue beat(8)2
Avg Revenue beat(8)55.45%
Revenue beat(12)2
Avg Revenue beat(12)16.36%
Revenue beat(16)4
Avg Revenue beat(16)46.83%
PT rev (1m)8.82%
PT rev (3m)15.06%
EPS NQ rev (1m)0.2%
EPS NQ rev (3m)0.2%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-11.11%
Revenue NY rev (3m)-13.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19444.92
P/FCF N/A
P/OCF N/A
P/B 1.52
P/tB 1.52
EV/EBITDA N/A
EPS(TTM)-3.75
EYN/A
EPS(NY)-3.77
Fwd EYN/A
FCF(TTM)-2.97
FCFYN/A
OCF(TTM)-2.91
OCFYN/A
SpS0
BVpS7.37
TBVpS7.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -41.41%
ROE -46.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 76.04%
Cap/Sales 10375.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.75
Quick Ratio 8.75
Altman-Z 4.09
F-Score2
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)209.37%
Cap/Depr(5y)259.38%
Cap/Sales(3y)3538.16%
Cap/Sales(5y)2134.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.85%
EPS Next Y-26.44%
EPS Next 2Y-12.42%
EPS Next 3Y-10.64%
EPS Next 5Y-6.84%
Revenue 1Y (TTM)-99.82%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%2900%
Revenue Next Year105.44%
Revenue Next 2Y47.6%
Revenue Next 3Y40.14%
Revenue Next 5Y132.6%
EBIT growth 1Y-6.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.11%
EBIT Next 3Y-20.55%
EBIT Next 5YN/A
FCF growth 1Y-73.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.51%
OCF growth 3YN/A
OCF growth 5YN/A

4D MOLECULAR THERAPEUTICS IN / FDMT FAQ

What is the fundamental rating for FDMT stock?

ChartMill assigns a fundamental rating of 3 / 10 to FDMT.


Can you provide the valuation status for 4D MOLECULAR THERAPEUTICS IN?

ChartMill assigns a valuation rating of 0 / 10 to 4D MOLECULAR THERAPEUTICS IN (FDMT). This can be considered as Overvalued.


How profitable is 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?

4D MOLECULAR THERAPEUTICS IN (FDMT) has a profitability rating of 1 / 10.